Acquired resistance to trastuzumab in both HER2-overexpressing breast and gastric cancer are associated with sustained Src-mediated activation of the MAPK/ERK and PI3K/mTOR pathways (82, 83). This evidence concerns the gene ERBB2 and gastric cancer.